Evidence map›Paper›PMID 27094551›Full record

ArticleMolecular pain2016

Rho/ROCK acts downstream of lysophosphatidic acid receptor 1 in modulating P2X3 receptor-mediated bone cancer pain in rats.

Jing-Xiang Wu, Xiao-Min Yuan, Qiong Wang, Wang Wei, Mei-Ying Xu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pain, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Neurotropin alleviates rat osteocarcinoma pain via PIranian journal of basic medical sciences · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. P2X receptor channels in chronic pain pathways.British journal of pharmacology · 2018
    Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jing-Xiang WuDepartment of Anesthesiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, PR China.
Xiao-Min YuanDepartment of Anesthesiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, PR China.
Qiong WangDepartment of Anesthesiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, PR China.
Wang WeiDepartment of Anesthesiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, PR China.
Mei-Ying XuDepartment of Anesthesiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, PR China my_xu55@163.com.
Shanghai Jiao Tong University · CNShanghai Chest Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLysophosphatidic acid receptor 1 and Rho/ROCK signaling is implicated in bone cancer pain development. However, it remains unknown whether the two signaling pathways function together in P2X3 receptor-mediated bone cancer pain.

resultsIn this study, using a rat model of bone cancer, we examined the expression of P2X3 and lysophosphatidic acid receptor 1 in rat dorsal root ganglion neurons and further dissected whether lysophosphatidic acid receptor 1 and Rho/ROCK-mediated pathways interacted in modulating rat pain behavior. Bone cancer was established by inoculating Walker 256 cells into the left tibia of female Wistar rats. We observed a gradual and yet significant decline in mean paw withdrawal threshold in rats with bone cancer, but not in control rats. Our immunohistochemical staining revealed that the number of P2X3- and lysophosphatidic acid receptor 1-positive dorsal root ganglion neurons was significantly greater in rats with bone cancer than control rats. Lysophosphatidic acid receptor 1 blockade with VPC32183 significantly attenuated decline in mean paw withdrawal threshold. Flinching behavior test further showed that lysophosphatidic acid receptor 1 inhibition with VPC32183 transiently but significantly attenuated α,β-meATP-induced increase in paw lift time per minute. Rho inhibition by intrathecal BoTXC3 caused a rapid reversal in decline in mean paw withdrawal threshold of rats with bone cancer. Flinching behavior test showed that BoTXC3 transiently and significantly attenuated α,β-meATP-induced increase in paw lift time per minute. Similar findings were observed with ROCK inhibition by intrathecal Y27632. Furthermore, VPC32183 and BoTXC3 effectively aborted the appearance of lysophosphatidic acid-induced calcium influx peak.

conclusionsLysophosphatidic acid and its receptor LPAR1, acting through the Rho-ROCK pathway, regulate P2X3 receptor in the development of both mechanical and spontaneous pain in bone cancer.

Indexed as

Signal TransductionAdenosine TriphosphateAnimalsBone NeoplasmsCalciumCancer PainFemaleGanglia, SpinalRats, WistarReceptors, Lysophosphatidic AcidReceptors, Purinergic P2X3rho-Associated Kinasesrho GTP-Binding ProteinsAdenosine Triphosphatealpha,beta-methyleneadenosine 5'-triphosphateCalciumReceptors, Lysophosphatidic AcidReceptors, Purinergic P2X3rho-Associated Kinasesrho GTP-Binding ProteinsBone cancer painlysophosphatidic acid receptorP2X3 receptorRho/ROCK

Identifiers

PMID27094551
PMCPMC4956381
OpenAlexW2340631821

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.